This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Boots Cough Syrup

OTC
Read time: 1 mins
Last updated: 29 Jul 2022
...
 

Summary of product characteristics


1. Name of the medicinal product

Infant Simple Cough Linctus 3 Months Plus or Infant Sugar Free Simple Cough Linctus or Children's 3 Months Plus Simple Cough Linctus or Boots Cough Syrup 3 Months Plus


2. Qualitative and quantitative composition

Active ingredient

% v/v

ml/5ml

Glycerol Ph Eur

15.0

0.75


3. Pharmaceutical form

Syrup


4.1. Therapeutic indications

For the relief of dry tickly coughs.


4.2. Posology and method of administration

For oral administration.

Children 3 months - 1 year: one 5ml spoonful three to four times a day.

Children 1 to 5 years: two 5ml spoonfuls three to four times a day.

Children under 3 months: not recommended.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

Not recommended for children under 3 months.

If symptoms persist for more than 3 days consult your doctor.

Keep all medicines out of the reach of children.


4.5. Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions.


4.6. Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established but is not thought to constitute a hazard.


4.7. Effects on ability to drive and use machines

No adverse effects known.


4.8. Undesirable effects

Immune system disorder: hypersensitivity reactions, including anaphylaxis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.


4.9. Overdose

Overdosage with this product may possibly cause diarrhoea. Treatment should be symptomatic.


5.1. Pharmacodynamic properties

Glycerin has demulcent properties and may possibly block sensory cough receptors in the respiratory tract.


5.2. Pharmacokinetic properties

None stated.


5.3. Preclinical safety data

Not applicable


6.1. List of excipients

Maltitol liquid

Hydroxyethylcellulose

Sodium benzoate

Citric acid monohydrate

Sodium citrate

Apple flavouring 5112OIE

Purified water


6.2. Incompatibilities

None stated


6.3. Shelf life

36 months


6.4. Special precautions for storage

Keep tightly closed.

Do not store above 25°C.


6.5. Nature and contents of container

1) Bottle amber PET with polypropylene child resistant closure fitted with expanded polythene liner.

Pack size: 100ml and 150 ml

2) Bottle amber glass with polypropylene child resistant closure fitted with an expanded polyethylene liner.

Pack size 100, 125ml or 150ml.


6.6. Special precautions for disposal and other handling

Not applicable


7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA

Trading as: BCM


8. Marketing authorisation number(s)

PL 00014/0500


9. Date of first authorisation/renewal of the authorisation

11/01/2007


10. Date of revision of the text

14/07/2015

4.1 Therapeutic indications

For the relief of dry tickly coughs.

4.2 Posology and method of administration

For oral administration.

Children 3 months - 1 year: one 5ml spoonful three to four times a day.

Children 1 to 5 years: two 5ml spoonfuls three to four times a day.

Children under 3 months: not recommended.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Not recommended for children under 3 months.

If symptoms persist for more than 3 days consult your doctor.

Keep all medicines out of the reach of children.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions.

4.6 Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established but is not thought to constitute a hazard.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Immune system disorder: hypersensitivity reactions, including anaphylaxis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Drug section

Journals
Journal
Bezlotoxumab for the prevention of Clostridium difficile recurrence.

Introduction:Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention...

1 mins
Journal
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Background: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy.

1 min
Journal
Faecal microbiota transplantation: a regulatory hurdle?

During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).